10-Q: AVITA Medical Reports First Quarter 2024 Results, Revenue Up 5.3% Amidst Increased Operating Expenses

AVITA Medical's first quarter 2024 results show a 5.3% increase in revenue, but also a significant rise in operating expenses leading to a larger net loss compared to the same period last year.

Summary

• AVITA Medical reported a 5.3% increase in total net revenues for the first quarter of 2024, reaching $11.1 million, compared to $10.6 million in the same period of 2023.
• Commercial revenue grew by 5.8% to $11.1 million, driven by deeper penetration within existing customer accounts and new accounts for full-thickness skin defects.
• The company's gross profit margin improved to 86.4% from 84.2% in the prior year, primarily due to increased revenues and lower shipping costs.
• Operating expenses increased by 38.0% to $26.8 million, compared to $19.4 million in the same period last year, with significant increases in sales and marketing expenses.
• Sales and marketing expenses rose by 93.3% to $12.6 million due to an expanded sales force, higher commissions, professional fees, and travel expenses.
• Research and development expenses increased by 13.3% to $5.2 million, mainly due to salaries, benefits, and share-based compensation, partially offset by lower professional fees.
• The company's net loss for the quarter was $18.7 million, or $0.73 per share, compared to a net loss of $9.2 million, or $0.37 per share, in the first quarter of 2023.
• Interest expense increased by approximately $1.4 million due to the OrbiMed Credit Agreement, with an aggregate principal amount owed of $40.0 million.
• The company had $17.0 million in cash and cash equivalents and $51.2 million in marketable securities as of March 31, 2024.
• AVITA Medical believes it has sufficient cash reserves to fund operations for the next 12 months.

Sentiment

Score: 4

Explanation: The document presents mixed results. While revenue increased and gross margins improved, the significant increase in operating expenses and net loss raises concerns. The company's future outlook is positive, but the current financial performance is a cause for caution.

Positives

• The company experienced a 5.3% increase in total net revenues and a 5.8% increase in commercial revenue.
• Gross profit margin improved to 86.4%, indicating better cost management in relation to revenue.
• The company has secured a multi-year distribution agreement with Stedical Scientific, Inc. for PermeaDerm.
• The company has extended its contract with BARDA to ensure access to RECELL inventory in the event of a national emergency.
• The company has sufficient cash reserves to fund operations for the next 12 months.

Negatives

• Operating expenses increased significantly by 38.0%, primarily driven by a 93.3% increase in sales and marketing expenses.
• The net loss for the quarter was $18.7 million, a substantial increase compared to the $9.2 million loss in the same period last year.
• Interest expense increased by $1.4 million due to the OrbiMed Credit Agreement.
• BARDA income decreased to zero, compared to $0.6 million in the corresponding period in the prior year due to reimbursable clinical trials winding down.

Risks

• The macroeconomic environment, including supply chain shortages, increased healthcare costs, inflation, and geopolitical conditions, may negatively impact the company's operating results.
• Changes in reimbursement rates by third-party payors may place additional financial pressure on hospitals and the broader healthcare system, potentially affecting demand for the company's products.
• The company's ability to achieve profitability is dependent on increasing sales of its products and managing operating expenses.
• The company is subject to minimum purchase requirements for PermeaDerm inventory, which could impact cash flow if sales do not meet expectations.
• The company's debt obligations under the OrbiMed Credit Agreement require meeting certain revenue targets, and failure to do so could trigger repayment obligations.

Future Outlook

The company aims to become the standard of care in the U.S. burns industry, expand into trauma centers, launch RECELL GO, and establish commercial payor coverage for RECELL in the U.S. for the treatment of vitiligo lesions, with initial coverage expected in the fourth quarter of 2025. The company also intends to continue to pursue business development opportunities that are complementary to its core RECELL indications and/or its targeted markets.

Management Comments

• The company is focused on becoming the leading provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo.
• The company will continue to drive commercial revenue growth to generate positive cash flow and achieve operating profit.

Industry Context

The company operates in the regenerative medicine and wound care market, which is experiencing growth due to advancements in technology and increasing demand for effective treatments. The company's focus on burn injuries, skin defects, and vitiligo aligns with unmet medical needs in these areas. The company's partnership with Stedical Scientific, Inc. for PermeaDerm expands its product portfolio and market reach.

Comparison to Industry Standards

• The company's revenue growth of 5.3% is moderate compared to some high-growth medical device companies, but it is important to consider the company's specific market focus and stage of development.
• The increase in operating expenses, particularly in sales and marketing, is a common trend for companies in the commercialization phase, as they invest in building their sales infrastructure and market presence.
• The company's gross profit margin of 86.4% is relatively high, indicating a strong pricing strategy and efficient cost management in production.
• The net loss of $18.7 million is significant, but it is not uncommon for companies in the medical device sector that are investing heavily in research, development, and commercialization.
• The company's cash position of $17.0 million and marketable securities of $51.2 million provide a reasonable runway for continued operations, but the company will need to carefully manage its cash burn rate.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the company's ability to achieve profitability.
• Employees may benefit from the company's expansion and growth, but may also be affected by any cost-cutting measures.
• Customers may benefit from the company's expanded product portfolio and increased availability of its products.
• Suppliers may benefit from the company's increased purchasing activity.
• Creditors may be concerned about the company's increased debt obligations and net loss.

Next Steps

• The company will continue to focus on increasing RECELL penetration and adoption in burn centers.
• The company will expand into U.S. trauma centers to increase utilization of RECELL for the treatment of full-thickness skin defects.
• The company will launch RECELL GO following FDA approval to increase market adoption and expand its customer base.
• The company will submit a PMA supplement for RECELL GO mini, which is designed to address smaller wounds.
• The company will expand its global presence within the European Union and Australia through the exclusive use of third-party distributors.
• The company will continue to build upon commercial activities in Japan through its partnership with COSMOTEC.
• The company will establish commercial payor coverage for RECELL in the U.S. for the treatment of vitiligo lesions, with initial coverage expected during the fourth quarter of 2025.

Key Dates

Keywords

RECELL System, PermeaDerm, wound care, regenerative medicine, burn treatment, skin defects, vitiligo, medical devices, distribution agreement, BARDA, financial results, operating expenses, revenue growth